JPRN-UMIN000006086已完成2 期
Efficacy and safety of Eribulin as the first line therapy for advanced or recurrent breast cancer patients without HER2 overexpression. - BIRICHEN study(Breast cancer multi Institutional study for Recurrent or Inoperable patients by first line CHemotherapy with EribuliN)
Dept. Surgical Oncology, Osaka City University Graduate School of Medicine0 个研究点目标入组 35 人开始时间: 2011年7月31日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)having systemic infection 2)pleural effusion,ascites,hydropericardium that is not good control 3)symptomatic brain metastasis 4)patient with following serious complication heart disease that is not good control myocardial infarction in the latest 6th months cirrhosis interstitial pneumonia,pulmonary fibrosis bleeding tendency 5)having active multiple cancers 6)menopausal women patients having possibility pregnancy 7)systemic steroid therapy 8)widespread radiation therapy 9)patient who reject supportive therapy for myelosuppresion 10)judged by the investigator to be unfit to be enrolled into the study
研究者
相似试验
已完成
不适用
Evaluation of safety and efficacy of eribulin for patients advanced or recurrent HER2 negative breast cancer who have been treated with anthracyclines and taxanesBreast cancerJPRN-UMIN000007121Kyushu Breast Cancer Study Group50
已完成
不适用
A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressingAdvanced or metastatic breast cancerJPRN-UMIN000009568General and Gastroenterological Surgery, Osaka Medical College35
尚未招募
不适用
Efficacy and safety of eribulin in combination with trastuzumab and pertuzumab for HER2-positive advanced breast cancerEligible patients were those with HER2-positive advanced breast cancer who had previously received trastuzumab (HER) + pertuzumab (PER) + taxanes and T-DM1, followed by HER + PER + eribulin.JPRN-UMIN000034477Keio University School of Medicine35
招募中
不适用
Exploratory clinical study of eribulin followed by taxane for metastatic breast cancer patientsMetastatic breast cancerJPRN-UMIN000027527Yamaguchi University Graduate School of Medicine30
已完成
不适用
Eribulin [Halaven] Use For the Treatment of Advanced Breast CancerMetastatic Breast CancerNCT02790320Eisai Farmacêutica S.A.112